Jubilant Organosys has strategically aligned its two entities, U.S.-based HollisterStier Laboratories and Canada-based Draxis Specialty Pharmaceuticals, and has assigned new leadership roles. The alignment is in an effort to leverage the strengths of these companies in the area of contract manufacturing of sterile injectables and non-sterile products and specialty pharmaceuticals. The unified operations will focus on R&D and product innovation for specialty pharmaceuticals, and will consolidate Jubilant’s sterile and non-sterile contract manufacturing with its multi-site capabilities.
   
Jean Pierre Robert has been appointed chief executive officer for the specialty pharmaceutical organization. He will be responsible for the radiopharmaceuticals business of Draxis as well as the allergy extracts business of HollisterStier. Marcelo Morales has been appointed chief executive officer for contract manufacturing. He will have responsibility for the sterile injectables manufacturing arm of HollisterStier and the sterile injectable, semisolids and solid dose manufacturing operations of Draxis.
   
“This strategic realignment will enable us to drive value for our customers through synergistic operations and will offer exciting opportunities for all of us,” said Jubilant Organosys co-chairmen Shyam and Hari Bhartia.